Issue 117 • April 2022

Covid-19 further burdens to CAR-T development

What next for Sputnik Covid-19 vaccine production?

Can NFTs allow people to monetise their health data?

In association with

Two years of Covid-19

What the pandemic taught us about delivering essential vaccines

In association with

03/24/2022 13:47:25
  • Home | Two years of Covid-19
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Controlant Company Insight
  • Controlant
  • Contract Pharmaceuticals Limited Canada
  • Comment
  • Ukraine: Russian invasion could cause spike in Covid-19 cases
  • First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvals
  • International Women’s Day spotlight: endometriosis
  • Remote audits – stopgap measure or the new normal?
  • Owen Mumford Company Insight
  • Owen Mumford
  • Baxter
  • In Depth
  • Two years of Covid-19: lessons the pandemic taught about delivering essential vaccines
  • A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-
  • Russia sanctions: what next for Sputnik Covid-19 vaccine production around the w
  • Profit for patients: can NFTs allow people to monetise their health data?
  • Navigating distribution challenges for rare disease drugs
  • Nipro
  • Datwyler Company Insight
  • Datwyler
  • In Data
  • North America is seeing a hiring boom in pharma digital media roles
  • Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021
  • Event: Outsourcing in Clinical Trials Europe 2022
  • Events
  • Next issue